Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by willibrichon Nov 05, 2010 7:34pm
703 Views
Post# 17667037

Don't worry be happy

Don't worry be happyMe thinks that there will be news before the market opens on Monday.
That way QEI can talk about the flow test results at today's meeting with Sprott in a meaningfull way. And why not ?

This is a pivotal moment for Quetzel. They are about to transistion from basically an oil exploration company to a junior oil company with some significant production and cash flow. And why should Quetzel not talk about operations going forward with basically their largest shareholder. It makes sense. 
But they can only reveal key information if the general public has access to the same information prior to the market opening.

And then, as has been mentioned before, the market will value QEI at a market cap consistent with their production and forecast cash flow.

It should be interesting. It appears that Colombian juniors  are in the spotlight right now. For example, I saw Loon Energy, LNE, ( 95 million shares out )  go from 5.5 cents to 17.5 cents on around 9 million shares traded over the last 2 days. This was on news of a discovery well with 117 feet of pay  (  the Visure1X well in Colombia ) , of which they hold 20 %. Now of course I believe that insiders hold around 40 % of LNE.........................nevertheless

Have a great weekend



    
Bullboard Posts